Gabapentin Capsule
Product Images NDC 0904-6667

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 0904-6667). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

4553d589 898d 45f2 A195 D6e6526a446b 00

Gabapentin capsules, USP 400 mg, oral dosage form, packaged in a unit dose blister card containing 100 capsules. The label shows the product manufactured by Major Pharmaceuticals with NDC 0904-6667-61. Each capsule contains 400 mg gabapentin. The label includes storage instructions and warnings, indicating Rx only status and directions to dispense the medication guide.*

FDA Label Image

4553d589 898d 45f2 A195 D6e6526a446b 01

Gabapentin 300 mg capsules label from Major Pharmaceuticals showing unit dose packaging. The label includes directions for pharmacists to dispense the Medication Guide and indicates 100 capsules per container. Storage instructions specify 20° to 25°C, and the label states the product is for institutional use only, not child resistant. Manufacturer and distributor information is also present.*

FDA Label Image

4553d589 898d 45f2 A195 D6e6526a446b 02

Gabapentin Capsules, USP 100 mg oral unit dose packaging label by Major Pharmaceuticals. The label states it contains 100 capsules, is for prescription use only, and instructs pharmacists to dispense the medication guide to each patient. Storage information specifies controlled room temperature (20° to 25°C). The label includes manufacturer and distributor details.*

FDA Label Image

Gabapentin-equation (Gabapentin Equation)

A text panel displaying a formula for calculating creatinine clearance (CLCr). The formula uses variables for age in years, weight in kilograms, serum creatinine in mg/dL, and includes a multiplication factor of 0.85 for female patients.*

FDA Label Image

Gabapentin-fig1 (Gabapentin Fig1)

A line chart depicting mean pain scores over an 8-week period comparing placebo and gabapentin 3600 mg/day. The x-axis represents weeks, divided into a 4-week dose titration period followed by a 4-week fixed dose period, while the y-axis shows mean pain scores from 0 to 10. Gabapentin scores decrease steadily over time, whereas placebo scores remain relatively stable.*

FDA Label Image

Gabapentin-fig2 (Gabapentin Fig2)

A line chart showing mean pain scores over a 7-week period comparing placebo with gabapentin at 1800 mg/day and 2400 mg/day. The x-axis represents weeks, including a 3-week dose titration period followed by a 4-week fixed dose period. The y-axis measures mean pain score from 0 to 10. Gabapentin groups demonstrate a decrease in mean pain scores over time compared to placebo.*

FDA Label Image

Gabapentin-fig3 (Gabapentin Fig3)

A bar chart titled 'Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing data from two studies. Study 1 compares placebo (12%) with Gabapentin 3600 mg (29%). Study 2 compares placebo (14%) with Gabapentin 1800 mg (32%) and Gabapentin 2400 mg (34%). Statistical significance is noted with p-values below 0.01 and 0.001 for treatment groups.*

FDA Label Image

Gabapentin-fig4 (Gabapentin Fig4)

A scatter plot chart showing percentage difference on the y-axis and daily dose in milligrams on the x-axis. The chart compares data points from three studies labeled a, b, and c, with study a represented by black squares, study b by gray squares, and study c by white squares. The data points illustrate variability in percentage difference across daily doses ranging from approximately 600 mg to 1800 mg.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.